RxDoctor Payments Data

Dean Okimoto, MD

Family Medicine · Yorba Linda, CANPI 1912908336

Payments from drug & device makers

$1,889in general payments, 2019–2025

Across 102 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$358
  • Johnson & Johnson$318
  • Novo Nordisk$218
  • Abbott$130
  • Sanofi-aventis U.S. LLC$127
  • Lilly USA, LLC$117
  • plus $620 from 11 others

What the payments were for

  • Consulting fees$201%
  • Food & beverage$1,83997%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,889 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$78,496
Medicare patients
251
Services billed
839

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$122,988
OzempicSemaglutide87$121,798
JardianceEmpagliflozin105$120,114
JanuviaSitagliptin Phosphate36$50,304
JanumetSitagliptin Phos/Metformin Hcl39$37,051
XareltoRivaroxaban23$18,369
MounjaroTirzepatide11$11,236
MyrbetriqMirabegron14$11,066
Rosuvastatin Calcium399$8,205
Levothyroxine Sodium479$7,154
VascepaIcosapent Ethyl12$6,996
Atorvastatin Calcium559$6,268
SynthroidLevothyroxine Sodium109$5,787
Losartan Potassium374$4,957
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$122,98895 claims
Novo NordiskOzempic$218$121,79887 claims
Boehringer IngelheimJardiance$109$120,114105 claims
MerckJanuvia, Janumet$40$87,35575 claims
Johnson & JohnsonXarelto$318$18,36923 claims
Lilly USA, LLCMounjaro$117$11,23611 claims
AbbVieSynthroid$78$5,787109 claims
GSKArexvy$86$4,39015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →